# Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

> **NCT00582738** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Recurrent Hepatitis C

## Interventions

- **DRUG:** CsA-TAC (standard Treatment)
- **DRUG:** Everolimus

## Key facts

- **NCT ID:** NCT00582738
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2012-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00582738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00582738, "Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00582738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*